the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.
Company profile
Ticker
DXR
Exchange
Website
CEO
Michael R. Feldschuh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
132682108
DXR stock data
Latest filings (excl ownership)
8-K
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
25 Mar 24
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
19 Mar 24
N-CEN
Annual report (registered investment company)
15 Mar 24
N-CSR
Certified annual shareholder report (management investment company)
15 Mar 24
NT-NCSR/A
Notice of inability to timely file Form N-CSR (amended)
8 Mar 24
NT-NCSR/A
Notice of inability to timely file Form N-CSR (amended)
29 Feb 24
NT-NCSR
Notice of inability to timely file Form N-CSR
29 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
8-K
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
2 Jan 24
8-K
Other Events
27 Nov 23
Transcripts
Latest ownership filings
4
Robert J Michel
27 Mar 24
4
Edward Feuer
6 Mar 24
4
Robert J Michel
6 Dec 23
4
Robert J Michel
1 Dec 23
4
Michael Richard Feldschuh
1 Dec 23
4
Robert J Michel
27 Nov 23
NPORT-P
None (Sep 2023 report)
24 Nov 23
4
Michael Richard Feldschuh
24 Nov 23
4
Michael Richard Feldschuh
13 Nov 23
4
Robert J Michel
2 Nov 23
Institutional ownership, Q2 2023
1.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 480.65 mm |
Total shares | 65.37 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 47.33 k | $454.35 mm |
Renaissance Technologies | 15.32 k | $147.00 k |
UBS UBS Group AG - Registered Shares | 2.45 k | $23.51 mm |
MS Morgan Stanley | 175.00 | $1.68 mm |
Tower Research Capital | 100.00 | $960.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Robert J Michel | Daxor Common Stock | Buy | Acquire P | No | No | 8.7 | 750 | 6.53 k | 11,300 |
4 Mar 24 | Edward Feuer | Daxor Common Stock | Buy | Acquire P | No | No | 7.21 | 1,000 | 7.21 k | 1,000 |
6 Dec 23 | Robert J Michel | Daxor Common Stock | Buy | Acquire P | No | No | 7.75 | 120 | 930.00 | 10,550 |
1 Dec 23 | Feldschuh Michael Richard | Daxor Common Stock | Buy | Acquire P | No | No | 7.8 | 800 | 6.24 k | 162,492 |
1 Dec 23 | Robert J Michel | Daxor Common Stock | Buy | Acquire P | No | No | 7.75 | 180 | 1.40 k | 10,430 |
News
Daxor Corporation Acquires Volumex And Megatope From Its Existing Supplier Along With Glofil To Enhance Existing Suite Of Diagnostics; No Financial Terms Disclosed
25 Mar 24
Daxor Announces As Of December 31, 2023, Daxor's Net Assets Were $34,010,384 Or $7.08 Per Share, Revenue Increased 31.8% Year On Year For 2023 Versus 2022, Provides Corporate Update In Letter To Shareholders
18 Mar 24
Daxor Announces Sales To Three New Hospitals Furthering Expansion Of Its User Base
11 Mar 24
Daxor Announces Two Significant New Customer Transactions With The Co's BVA-100 In January; No Financial Terms Disclosed
12 Feb 24
Daxor Corporation Closes Q4 2023 With Growth In New Sales To Hospital Systems And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Across The U.S. At Existing Accounts
7 Feb 24
Press releases
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
22 Mar 24
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts
7 Feb 24